Company Overview and News

0
Emerald Health Therapeutics Completes Acquisition of Licensed Dealer Northern Vine Canada

2018-08-15 globenewswire
VICTORIA, British Columbia, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (Emerald) has completed the purchase of the remaining shares of Northern Vine Canada Inc. (Northern Vine) from Abattis Bioceuticals Corp. (Abattis) (CSE: ATT; OTC: ATTBF) for $2 million in cash and 1,093,938 common shares of Emerald (with a deemed value of $4 million, based on the trailing 30 day VWAP of Emerald shares as of July 19, 2018).
ATTBF EMH TBQBF EMHTF ATT

106
8 Pot Stocks That Can Rise Above Marijuana Controversies

2018-08-03 investorplace - 2
Sound investing principles call for a healthy serving of stable, dividend-paying, blue-chip companies. But let’s be honest: sound investing can also be incredibly boring. A big draw of market participation is to get in early on megatrends that others don’t see or find too risky.
STZ.B TWMJF ACB EMH TBQBF EMHTF CRON WEED ACBFF STZ CGC SMG

0
Village Farms International, Inc. Faces Formidable Headwinds

2018-08-03 seekingalpha
Pros and cons concerning if it will be able to reach asserted potential from its JV with Emerald Health Therapeutics.
EMH TBQBF EMHTF VFFIF

0
Abattis Continues to Build on Recent Investments With Plans for Significant Revenue Growth

2018-07-31 globenewswire
VANCOUVER, British Columbia, July 31, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to provide an update as the Company moves to a phase of building on recent investments and anticipates significant revenue growth in the fourth quarter of 2018.
ATTBF EMH TBQBF EMHTF ATT

0
Emerald Health Therapeutics’ Cannabis Joint Venture Pure Sunfarms Receives Sales License from Health Canada for 1.1 Million Square Foot Greenhouse

2018-07-30 globenewswire
VANCOUVER, British Columbia, July 30, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSX-V:EMH) (OTCQX:EMHTF) (“Emerald”) and Village Farms International, Inc. (“Village Farms”) (TSX:VFF) (OTC:VFFIF) today announced that their 50/50 joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has received its cannabis sales license from Health Canada. Pure Sunfarms is now permitted to immediately begin selling product from its expanding inventory of high-quality dried cannabis, including to Emerald Health Therapeutics, under their previously announced supply agreement, as well as to address significant demand from other licensed producers.
EMH TBQBF EMHTF VFFIF VFF

679
Stocks To Watch: FANGs Out In Tech

2018-07-21 seekingalpha - 4
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
YUM AROC TCAP HYRE ABT CRM BXS BHC CHFC RGA CSCO TBIO UXIN CAH PKD MS HSY GWP SNAP NCMI FOX JCOM HOMB AMC GILD MNLO UTX SYF MDT CYS EXPE ACB GWPH EMHTF JNJ ALV VZ APHQF VNE LMT FB OLED STIM NFLX BAX EHC SKX BAC ZION OKE.WI CL FPBK TCCB OKE TCCA INTC AGS CBS UL WYNN EVER MA GSK FNSR TCDA UA FFKT NTGN HAS FNKO SBUX CAKE APTV TXN TBQBF XOM ACBFF TWX UAA RF RDI IMAX CNK GTES AMZN TWTR HMNY TWO EBAY BBT ARMO BAC CMA EYEN CRON BV TCC MDLZ CMG PFS BJ GOOGL LVS QCOM FOXA PFE LOVE WFCNP HAL PM HRB WWW GPC PYPL PAGS DLPH MCS PFG TWMJF RDIB AMCX WEED ACN DIS MCD ABT WFC QRVO MJN F SLDB BRY CMCSA K CGC SNPS EMH T MRK CVX FTSV SNE LITE MEDFF PZZA TILE

8
Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors

2018-07-20 globenewswire - 1
FRAMINGHAM, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™ (“AC5™”), today announced the appointment of Punit Dhillon, former President & CEO of OncoSec Medical, Inc. (NASDAQ:ONCS), to its Board of Directors (the “Board”) as an independent member effective as of July 19, 2018. Mr. Dhillon brings over 15 years of global industry experience to Arch’s Board with a wealth of knowledge and experience operationally in medical devices, advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally.
NMUS EMH ARTH INO TBQBF EMHTF ONCS

2
Emerald Health: Why Did This Stock Tank 60% In 2018?

2018-07-19 seekingalpha - 2
Our February article highlighted several risks related to insiders, crypto distractions and unproven ability to execute.
EMH TBQBF EMHTF APHQF

0
Abattis Enters Into Definitive Agreement to Sell Northern Vine Interest

2018-07-19 globenewswire
VANCOUVER, British Columbia, July 19, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce that it has entered into a definitive agreement (the “Agreement”) with Emerald Health Therapeutics, Inc. (“Emerald”) to dispose of (the “Disposition”) its 35% interest in Northern Vine Canada Inc. (“Northern Vine”) in exchange for $2 million in cash and $4 million in freely tradeable common shares of Emerald.
ATTBF EMH TBQBF EMHTF ATT

0
Emerald Health Therapeutics Completes Full Acquisition of Licensed Dealer Northern Vine to Advance Product Innovation

2018-07-19 globenewswire
VICTORIA, British Columbia, July 19, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (Emerald) has signed a definitive agreement (“Agreement”) to acquire the remaining shares of Northern Vine Canada Inc. (Northern Vine), owned by Abattis Bioceuticals Corp. (Abattis) (CSE:ATT) (OTC:ATTBF), for $2 million in cash and $4 million in shares of Emerald stock. This transaction increases Emerald’s ownership of Northern Vine from 65% to 100%.
ATTBF EMH TBQBF EMHTF ATT

92
Canadian Cannabis Outlook: Winners And Losers In British Columbia

2018-07-13 seekingalpha - 2
Only a few of those MOUs have included quantity figures, including Canopy Growth, Aphria, and Maricann.
TWMJF EMH TBQBF EMHTF WEED APHQF CGC

0
Emerald Health Therapeutics Updates on its Differentiated Strategy and Progress

2018-07-12 globenewswire
VICTORIA, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (Emerald) is providing an update on its differentiated strategy to excel in the growing cannabis industry.
EMH TBQBF EMHTF

92
TD Bank to acquire Saskatchewan-based Greystone Managed Investments

2018-07-10 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
TNTTF TBQBF ACBFF CGC TD EMH TWMJF ACB APH EMHTF WEED APHQF TD

4
Emerald Health Therapeutics Announces Amendment to Pure Sunfarms’ Cultivation License, Substantially Expanding Cannabis Production Area to 225,000 Square Feet

2018-06-27 globenewswire
VANCOUVER, British Columbia, June 27, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSX-V:EMH) (OTCQX:EMHTF) (“Emerald”) and Village Farms International, Inc. (“Village Farms” or the “Company”) (TSX:VFF) (OTC:VFFIF) today announced that their 50/50 joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada an amendment to its cultivation license for its Delta 3 greenhouse in Delta, BC.
EMH TBQBF EMHTF VFFIF VFF

4
Emerald Health Therapeutics Welcomes Historic Passing of Bill C-45 to Legalize Adult-Use Cannabis in Canada

2018-06-19 globenewswire
VICTORIA, British Columbia, June 19, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (Emerald) today applauds the Canadian government’s historic passing of Bill C-45 (Cannabis Act) to end Canada’s near century-long prohibition of recreational cannabis and usher in a new era of cannabis regulation.
EMH TBQBF EMHTF

TBQBF: Emerald Health Therapeutics (TSXV:EMH) Analysis and Research Report

2017-12-14 - Asif

Emerald Health Therapeutics, Inc. was incorporated pursuant to the Business Corporations Act (British Columbia) on July 31, 2007 as Firebird Capital Partners Inc. and changed its name to Firebird Energy Inc. in December 2012. On September 4, 2014, the Company completed the acquisition of all the issued and outstanding common shares of Thunderbird Biomedical Inc. (“Thunderbird”), by way of a reverse takeover (the “Transaction”) under the rules of the TSX Venture Exchange (the “TSXV”) and concurrently changed its name to T-Bird Pharma, Inc. At that time, Thunderbird became a wholly-owned subsidiary of T-Bird. In June 2015, the Company changed its name to Emerald Health Therapeutics, Inc. and Thunderbird changed its name to Emerald Health Botanicals Inc. (“Botanicals”). The Company is a publicly traded company with headquarters in Victoria, British Columbia, Canada. Common shares of the Company (the “Common Shares”) are listed on the TSXV under the trading symbol “EMH”. The Company is ...

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 29102R106